Profile
Eli M.
Wallace worked as a Director of Medicinal Chemistry at Array BioPharma, Inc. from 2009 to 2011.
Prior to that, he worked as a Medicinal Chemist at Glaxo Wellcome Plc, Novartis AG, GSK Plc, and Ciba-Geigy AG.
He also served as the Chief Scientific Officer at Peloton Therapeutics, Inc. and BridgeBio Pharma, Inc. Dr. Wallace received his doctorate degree from Colorado State University in 1993 and his undergraduate degree from Lawrence University.
Former positions of Eli M. Wallace
| Companies | Position | End |
|---|---|---|
| ARRAY TECHNOLOGIES, INC. | Corporate Officer/Principal | 31/12/2010 |
| BRIDGEBIO PHARMA, INC. | Chief Tech/Sci/R&D Officer | - |
| GSK PLC | Corporate Officer/Principal | - |
| Glaxo Wellcome Plc | Corporate Officer/Principal | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Training of Eli M. Wallace
| Lawrence University | Undergraduate Degree |
| Colorado State University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| NOVARTIS AG | Health Technology |
| GSK PLC | Health Technology |
| BRIDGEBIO PHARMA, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Peloton Therapeutics, Inc.
 Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Ciba-Geigy AG
 Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Health Technology |
| Glaxo Wellcome Plc | Health Technology |
- Stock Market
- Insiders
- Eli M. Wallace
